<DOC>
	<DOCNO>NCT00489424</DOCNO>
	<brief_summary>This study evaluate efficacy acetaminophen fluvastatin reduce rate occurrence severity post dose symptom may occur 3 day period follow zoledronic acid infusion post menopausal woman low bone mass .</brief_summary>
	<brief_title>Acetaminophen Fluvastatin Compared Placebo Transient Post-Dose Symptoms ( PDS ) Following Intravenous ( i.v . ) Infusion Single Dose Zoledronic Acid 5mg , Post-menopausal Women With Low Bone Mass</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>1 . Postmenopausal woman great equal 45 less equal 79 year age randomization 2 . Women clinically indicate treatment Bisphosphonates osteopenia osteoporosis document central ( spine hip ) Bone Mineral Density T Score less equal 1.5 1 . Any prior treatment intravenous Bisphosphonates 2 . Oral treatment Bisphosphonates 8 week within 6 month prior screen visit 3 . Patients take , unwilling unable stop taking , certain medication 4 . Patients require anticoagulant therapy 5 . Patients know hypersensitivity ibuprofen , ACET , bisphosphonates , statins allergy manifest attack asthma , urticaria acute rhinitis follow 6 . Proteinuria ( protein detect urine dipstick ) great equal 2+ screen 7 . Protocol specific laboratory value fall range study 8 . Ongoing infection ( oral body temperature great equal 37.5C ( 99.5Â°F ) , chronic febrile disease fever unknown origin screen randomization 9 . Active dental infection , unhealed dental extraction plan oral surgery within 3 month randomization 10 . History iritis , uveitis chronic conjunctivitis 11 . History hypoparathyroidism , hyperparathyroidism Paget 's Disease 12 . Partial total removal parathyroid thyroid gland 13 . History malignancy organ system , treat untreated , within past 1 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin 14 . Treatment investigational drug within previous 30 day screen 15 . Patients medical psychiatric condition , opinion Principal Investigator , would preclude participant adhere protocol complete trial per protocol , patient Principal Investigator think participate study reason , include current drug alcohol abuse Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>zoledronic acid</keyword>
	<keyword>post dose symptom</keyword>
	<keyword>transient</keyword>
	<keyword>acetaminophen</keyword>
	<keyword>fluvastatin</keyword>
</DOC>